DUBLIN--(BUSINESS WIRE)--The "Sickle Cell Disease Drug Development Pipeline Review, 2017" report has been added to Research and Markets' offering.
This report provides an overview of the Sickle Cell Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for sickle cell anemia and vaso-occlusive crisis associated with sickle cell disease, and features dormant and discontinued projects.
Key companies operating in this pipeline space include Acceleron Pharma, Epidestiny, Errant Gene Therapeutics, Gamida Cell, Global Blood Therapeutics, Hillhurst Biopharmaceuticals, Novartis and Regenacy Pharmaceuticals. Hemoglobin and a range of histone deacetylases are the most common molecular targets being studied in sickle cell anemia.
Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. There are a total of 10 products in development for this indication, by nine companies.
- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Key Topics Covered:
1 List of Tables & Figures
2.1 Sickle Cell Disease Report Coverage
2.2 Sickle Cell Disease - Overview
2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview
3 Therapeutics Development
3.1 Sickle Cell Disease
3.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
4 Therapeutics Assessment
4.1 Sickle Cell Disease
4.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
5 Companies Involved in Therapeutics Development
5.1 Sickle Cell Disease
5.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
6 Dormant Projects
6.1 Sickle Cell Disease
6.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
7 Discontinued Products
7.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
8 Product Development Milestones
8.1 Sickle Cell Disease
8.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease
For more information about this report visit https://www.researchandmarkets.com/research/bdhst4/sickle_cell?w=4